<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>The Biotech Growth Trust Plc — News on 6ix</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc</link>
<description>Latest news and press releases for The Biotech Growth Trust Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 09:31:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/the-biotech-growth-trust-plc" rel="self" type="application/rss+xml" />
<item>
<title>Monthly Fact Sheet as at 31 March 2026</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-march-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-march-2026-5</guid>
<pubDate>Mon, 13 Apr 2026 09:31:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet as at 31 March 2026, which is now available on the company's website. This announcement provides investors with updated performance and portfolio information for the trust.
Disclaimer*</description>
</item>
<item>
<title>Biogen, Inc. to acquire BIOG portfolio compan...</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/biogen-inc-to-acquire-biog-portfolio-compan</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/biogen-inc-to-acquire-biog-portfolio-compan</guid>
<pubDate>Wed, 01 Apr 2026 06:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC announced that its portfolio company, Apellis Pharmaceuticals, Inc., is being acquired by Biogen Inc. for approximately $5.6 billion in cash, or $41 per share, representing a 140% premium. This offer could increase to a 163% premium with an additional $4 per share in contingent value rights tied to sales milestones. Apellis, which has two approved complement pathway drugs, EMPAVELI and SYFOVRE, generated $689 million in net product revenues in 2025 and expects mid-to</description>
</item>
<item>
<title>Net Asset Value(s)</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/net-asset-values-286</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/net-asset-values-286</guid>
<pubDate>Fri, 27 Mar 2026 13:35:00 GMT</pubDate>
<description>Net Asset Value(s).</description>
</item>
<item>
<title>Kepler Trust Intelligence: New Research</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/kepler-trust-intelligence-new-research-82</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/kepler-trust-intelligence-new-research-82</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>Biotech Growth Trust PLC has seen its share price soar due to renewed interest in the biotechnology sector. Kepler Trust Intelligence has released new research on the trust, offering a comprehensive reference for long-term investors, which is available for free to UK investors. The report, issued by Kepler Partners LLP, notes a potential conflict of interest as the firm has a relationship with the company being covered. Investors are reminded that past performance is not indicative of future res</description>
</item>
<item>
<title>Monthly Fact Sheet as at 28 February 2026</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-28-february-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-28-february-2026-4</guid>
<pubDate>Wed, 11 Mar 2026 14:08:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet for the period ending 28 February 2026, which is now accessible on the company's website. This update provides shareholders with the latest performance data and portfolio information for the trust.
Disclaimer*</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/transaction-in-own-shares-267</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/transaction-in-own-shares-267</guid>
<pubDate>Fri, 06 Mar 2026 17:12:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has purchased 115,000 of its own ordinary shares at 1243.20 pence per share for cancellation, utilizing part of the authority granted at its November 12, 2025 General Meeting to buy back up to 3,291,239 shares. Following this transaction, the total number of voting rights in the Company is now 20,314,314, which shareholders can use for disclosure calculations under the FCA's rules. The Company currently holds no shares in treasury.
Disclaimer*</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/total-voting-rights-485</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/total-voting-rights-485</guid>
<pubDate>Mon, 02 Mar 2026 10:11:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has announced that as of February 28, 2026, its total issued ordinary share capital comprises 20,429,314 ordinary shares of 25p each, with each share carrying one voting right. Consequently, the total number of voting rights in the Company is 20,429,314. This figure serves as the denominator for shareholders to calculate potential notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules regarding their interests in </description>
</item>
<item>
<title>Investor Webinar</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/investor-webinar-17</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/investor-webinar-17</guid>
<pubDate>Mon, 02 Mar 2026 07:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC announced an investor webinar scheduled for Wednesday, March 11, 2026, at 3pm GMT, where portfolio managers will discuss investment performance and future positioning. The company highlighted a positive outlook for the biotech sector, driven by rate-cutting cycles, reduced political concerns, M&A opportunities, and ongoing innovation, suggesting a recovery in valuations. The webinar is open to existing and prospective shareholders and will be available on the Frostro</description>
</item>
<item>
<title>Monthly Fact Sheet as at 31 January 2026</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-january-2026</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-january-2026</guid>
<pubDate>Thu, 12 Feb 2026 12:03:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet for January 2026, which is now available on the company's website. This update provides shareholders with the latest performance data and portfolio information as of January 31, 2026.
Disclaimer*</description>
</item>
<item>
<title>Investor Presentation via Investor Meet Compa...</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/investor-presentation-via-investor-meet-compa-5</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/investor-presentation-via-investor-meet-compa-5</guid>
<pubDate>Wed, 11 Feb 2026 11:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has announced an investor presentation by co-portfolio manager Josh Golomb of OrbiMed Advisors LLC on March 10, 2026, at 16:00 GMT, accessible via Investor Meet Company. This presentation is open to all current and prospective shareholders, with the opportunity to submit questions by March 9, 2026, at 09:00 GMT, or during the live event.
Disclaimer*</description>
</item>
<item>
<title>Monthly Fact Sheet as at 31 December 2025</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-december-2025</guid>
<pubDate>Thu, 15 Jan 2026 14:32:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet for the period ending 31 December 2025, which is now accessible on the company's website. This update provides key performance data and financial information relevant to investors.
Disclaimer*</description>
</item>
<item>
<title>BioMarin Pharmaceuticals to acquire BIOG port...</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/biomarin-pharmaceuticals-to-acquire-biog-port</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/biomarin-pharmaceuticals-to-acquire-biog-port</guid>
<pubDate>Mon, 22 Dec 2025 12:55:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC notes that BioMarin Pharmaceuticals will acquire Amicus Therapeutics, a portfolio company, for approximately $4.8 billion, or $14.50 per share, representing a 33% premium. This acquisition will enhance BioMarin's commercial portfolio by adding two new treatments and a potential first-in-class investigational drug for a rare kidney disease. The Biotech Growth Trust's holding in Amicus represented 2.7% of its net asset value at the time of the announcement, and this tr</description>
</item>
<item>
<title>Monthly Fact Sheet as at 30 November 2025</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-30-november-2025</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-30-november-2025</guid>
<pubDate>Fri, 12 Dec 2025 14:24:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet for the period ending 30 November 2025, which is now accessible on the company's website. This update provides key performance data and financial information relevant to investors.
Disclaimer*</description>
</item>
<item>
<title>Director Declaration</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/director-declaration-176</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/director-declaration-176</guid>
<pubDate>Tue, 02 Dec 2025 15:31:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has announced that non-executive director Hamish Baillie will also serve as a non-executive director for Fidelity Special Values PLC, effective January 1, 2026, in compliance with UK Listing Rule 6.4.9. This appointment is a direct notification to the market regarding a change in directorship for a key individual within the company.
Disclaimer*</description>
</item>
<item>
<title>Half-year Financial Report</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/half-year-financial-report-33</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/half-year-financial-report-33</guid>
<pubDate>Thu, 20 Nov 2025 07:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC reported a strong first half of the financial year ending 30 September 2025, with Net Asset Value (NAV) per share increasing by 36.9% to 1,117.2p, significantly outperforming its benchmark. This growth was driven by a resurgence in small-cap biotech stocks, with key contributors including Mineralys Therapeutics, Alnylam Pharmaceuticals, and Avidity Biosciences. The company's share price also saw a substantial rise of 33.3% to 1,005.0p, though it traded at a 10.0% dis</description>
</item>
<item>
<title>Result of General Meeting</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/result-of-general-meeting-166</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/result-of-general-meeting-166</guid>
<pubDate>Wed, 12 Nov 2025 16:37:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC announced that shareholders overwhelmingly approved a special resolution at a General Meeting to renew the company's authority to buy back up to 14.99 per cent. of its issued share capital. The resolution passed with 5,493,235 votes in favour, representing 99.7 per cent. of votes cast, against only 15,911 votes against. This approval allows the company to continue its share repurchase program, which could impact the stock's value. The total number of ordinary shares </description>
</item>
<item>
<title>Monthly Fact Sheet as at 31 October 2025</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-october-2025</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/monthly-fact-sheet-as-at-31-october-2025</guid>
<pubDate>Wed, 12 Nov 2025 11:13:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC has released its monthly fact sheet for the period ending 31 October 2025, which is now accessible on the company's website. This update provides key performance indicators and portfolio details relevant to investors.
Disclaimer*</description>
</item>
<item>
<title>Compliance with Market Abuse Regulation</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/compliance-with-market-abuse-regulation-18</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/compliance-with-market-abuse-regulation-18</guid>
<pubDate>Tue, 21 Oct 2025 06:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC confirms that all inside information has been disclosed and that its net asset value per share is calculated and announced daily. The company anticipates no material difference between the net asset value per share as of September 30, 2025, which was announced on October 1, 2025, and the financial information to be published in the upcoming half-year results announcement for the period ending September 30, 2025. Consequently, the company is permitted to deal in its o</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/directorpdmr-shareholding-486</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/directorpdmr-shareholding-486</guid>
<pubDate>Wed, 15 Oct 2025 14:17:00 GMT</pubDate>
<description>Julie Tankard, a Non-executive Director of The Biotech Growth Trust PLC, has made an initial notification regarding the acquisition of shares. On October 15, 2025, Tankard acquired 369 ordinary 25p shares on the London Stock Exchange (XLON). The price per share was 1,072.0831 pence. The total aggregated volume of shares acquired was 369, at an aggregated price of 1,072.0831 pence per share.
Disclaimer*</description>
</item>
<item>
<title>Publication of a circular and notice of gener...</title>
<link>https://6ix.com/company/the-biotech-growth-trust-plc/news/publication-of-a-circular-and-notice-of-gener</link>
<guid isPermaLink="true">https://6ix.com/company/the-biotech-growth-trust-plc/news/publication-of-a-circular-and-notice-of-gener</guid>
<pubDate>Wed, 15 Oct 2025 07:00:00 GMT</pubDate>
<description>The Biotech Growth Trust PLC is seeking shareholder approval at a General Meeting on November 12, 2025, to renew its authority to buy back ordinary shares. Shareholders previously approved a buy back authority for up to 14.99 percent of issued share capital at the Annual General Meeting on July 17, 2025. As of the latest practicable date, the company has repurchased 2,710,338 shares, representing 10.7 percent of the issued share capital at the time of the initial buy back approval. The board ant</description>
</item>
</channel>
</rss>